Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)

Abstract

We examined safety and efficacy of STI-571 in 24 bcr/abl-positive patients with CML post PBSCT. At start of STI-571 therapy, nine patients presented in blast crisis (BC) or in accelerated phase (AP), and 15 in chronic phase (CP). Patients were evaluated for hematologic, cytogenetic and molecular response, survival and toxicity. In general, STI-571 was well tolerated in this heavily pretreated group of patients with a non-hematologic and hematologic toxicity profile similar to that observed in a previous phase I trial at comparable doses. Five of nine patients with CML in transformation (AP, BC) were evaluable for hematologic response. Two of five patients had transient reductions in WBC and blasts, and three patients achieved a sustained hematologic response (>4 weeks). Cytogenetic analysis in these patients revealed numerical and/or structural responses. In CML chronic phase, STI-571 induced complete hematologic responses in all patients and major cytogenetic responses in 61% of patients with a complete cytogenetic response rate of 46%. This report indicates that STI-571 is a safe and effective drug in heavily pretreated patients. No apparent additional side-effects were noted in this patient cohort. The high rate of complete hematologic and complete cytogenetic responses in CP patients is remarkable, as intensive treatment approaches plus IFN-alpha failed to be efficient in achieving long-term stabilization of CML in this patient cohort.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Goldman JM, Druker BJ . Chronic myeloid leukemia: current treatment options Blood 2001 98: 2039–2042

    Article  CAS  PubMed  Google Scholar 

  2. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S . An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemias: developed for the American Society of Hematology Blood 1999 94: 1517–1536

    CAS  PubMed  Google Scholar 

  3. Hehlmann R, Hochhaus A, Berger U, Reiter A . Current trends in the management of chronic myelogenous leukemia Ann Hematol 2000 79: 345–354

    Article  CAS  PubMed  Google Scholar 

  4. Italian Cooperative Study Group on CML. IFN-alpha2a as compared with conventional chemotherapy for the treatment of CML N Engl J Med 1994 330: 820–825

  5. Chronic Myeloid Leukemia Triallists’ Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials J Natl Cancer Inst 1997 89: 1616–1620

  6. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barett M, Reiffers J, Simonsson B, Carella A, Aeppli D . Autologous transplants for chronic myelogenous leukaemia: results Lancet 1994 343: 486–488

    Article  Google Scholar 

  7. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, Hester J, Korbling M, Durett A, Moen R, Berenson R, Heimfeld S, Hamer J, Clavert L, Tibbits P, Talpaz M, Kantarjian H, Champlin R, Reading C . Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML Blood 1994 83: 3068–3076

    CAS  PubMed  Google Scholar 

  8. Rowley JD . A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining Nature 1973 243: 290–293

    Article  CAS  PubMed  Google Scholar 

  9. Sawyers CL . Chronic myeloid leukaemia N Engl J Med 1999 340: 1330–1340

    Article  CAS  PubMed  Google Scholar 

  10. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E . Alternative splicing of RNAs transcribed from the human abl gene and from the BCR/ABL fused gene Cell 1986 27: 277–284

    Article  Google Scholar 

  11. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D . The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene Science 1986 233: 212–214

    Article  CAS  PubMed  Google Scholar 

  12. Heisterkamp N, Jenster G, tenHoeve J, Zovich D, Pattengale PK, Groffen J . Acute leukemia in bcr/abl transgenic mice Nature 1990 344: 251–253

    Article  CAS  PubMed  Google Scholar 

  13. Daley GQ, Van Etten RA, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 1990 247: 824–830

    Article  CAS  PubMed  Google Scholar 

  14. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N . Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL Proc Natl Acad Sci USA 1990 87: 6649–6653

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Elefanty AG, Hariharan IK, Cory S . Bcr/abl, the hallmark of chronic myelogenous leukemia in man, induces multiple hematopoietic neoplasms in mice EMBO J 1990 9: 1069–1078

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kindler T, Meyer RG, Fischer T . BCR-ABL as a target for novel therapeutic interventions Exp Opin Ther Targets 2002 6: 85–101

    Article  CAS  Google Scholar 

  17. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB . Inhibition of the Abl protein-tyrosin kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 1996 56: 100–104

    CAS  PubMed  Google Scholar 

  18. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB . Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells Nat Med 1996 2: 561–566

    Article  CAS  PubMed  Google Scholar 

  19. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase Science 2000 289: 1938–1942

    Article  CAS  PubMed  Google Scholar 

  20. Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031–1037

    Article  CAS  PubMed  Google Scholar 

  21. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M . Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of CML and ALL with the Philadelphia chromosome N Engl J Med 2001 344: 1038–1042

    Article  CAS  PubMed  Google Scholar 

  22. Sawyers CL, Hochhaus A, Silver RT, Goldman JM, Miller C, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Niederwieser D, Fischer T, O'Brien SG, Stone R, Corneo G, Russell N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S, Morra E, Larsen R, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker B . Glivec (imatinib mesylate) induces hematologic and cytogenetic responses in patients with CML in myeloid blast crisis: results of a phase II study Blood 2002 99: 3530–3539

    Article  CAS  PubMed  Google Scholar 

  23. Talpaz M, Silver RT, Druker B, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL . Glivec (imatinib mesylate) induces durable hematologic and cytogenetic responses in patients with accelerated phase CML: results of a phase II study Blood 2002 99: 1928–1937

    Article  CAS  PubMed  Google Scholar 

  24. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B . Glivec (imatinib mesylate) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in chronic phase: results of a phase II study N Engl J Med 2002 346: 645–652

    Article  CAS  PubMed  Google Scholar 

  25. Hess G, Reifenrath C, Friedrich-Freksa A, Beyer V, Naumann S, Schuch B, Huber C, Fischer T, Decker HJ . Autologous transplantation of in vivo purged PBSC in CML: comparison of FISH, cytogenetics, and PCR detection of Philadelphia chromosome in leukapheresis products Cancer Genet Cytogenet 2000 117: 1–8

    Article  CAS  PubMed  Google Scholar 

  26. Cross NC, Melo JV, Feng L, Goldman JM . An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders Leukemia 1994 8: 186–189

    CAS  PubMed  Google Scholar 

  27. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A . Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR Leukemia 1999 13: 1825–1832

    Article  CAS  PubMed  Google Scholar 

  28. Fischer T, Neubauer A, Mohm J, Huhn D, Busemann C, Link H, Arseniev L, Bussing B, Novotny J, Ganser A, Duyster J, Bunjes D, Westermeier T, Flohr T, Despres D, Gamm H, Decker J, Derigs G, Aulitzky W, Huber C . Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied Ann Hematol 1998 77: 21–26

    Article  CAS  PubMed  Google Scholar 

  29. Fischer T, Neubauer A, Mohm J, Huhn D, Busemann C, Link H, Arseniev L, Bussing B, Novotny J, Ganser A, Duyster J, Bunjes D, Kreiter S, Aulitzky W, Hehlmann R, Huber C . Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML Bone Marrow Transplant 1998 21: 1029–1036

    Article  CAS  PubMed  Google Scholar 

  30. Deininger MW, Goldman JM, Lydon N, Melo JV . The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells Blood 1997 90: 3691–3698

    CAS  PubMed  Google Scholar 

  31. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC . Molecular heterogeneity in complete cytogenetic responders after interferon alpha therapy for chronic myeloid leukemia: low levels of minimal residual disease are associated with continuing remission Blood 2000 95: 62–66

    CAS  PubMed  Google Scholar 

  32. Fang G, Naekyung Kim C, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN . CCGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs Blood 2000 96: 2246–2253

    CAS  PubMed  Google Scholar 

  33. Thiesing TJ, Ohno-Jones S, Kolibaba KS, Druker BJ . Efficacy of STI-571, an ABL tyrosine kinase inhibitor, in conjunction with other antileukemic agents against BCR-ABL-positive cells Blood 2000 96: 3195–3199

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Deutsche José Carreras Leukämie-Stiftung eV and a research grant from Novartis Pharmaceuticals.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fischer, T., Reifenrath, C., Hess, G. et al. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Leukemia 16, 1220–1228 (2002). https://doi.org/10.1038/sj.leu.2402565

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402565

Keywords

This article is cited by

Search

Quick links